Macrophage activation marker sCD163 and sCD206 predict mortality in patients with alcoholic hepatitis
AASLD LiverLearning®, Banishree Saha, 144128
Sustained viral clearance of HCV with DAA treatment is associated with restoration of effector T cell phenotype
AASLD LiverLearning®, Asma Ahmed, 144384
Ethanol-Induced Alterations in Pancreatic and Gastric Hormone Secretion Promotes Hepatic Steatosis
AASLD LiverLearning®, Karuna Rasineni, 144129
Longitudinal changes in peripheral CD4+ regulatory T cells upon treatment of chronic hepatitis C with direct-acting antivirals
AASLD LiverLearning®, Bettina Langhans, 144385
Analysis of immune responses in hepatocellular carcinoma patients vaccinated with alpha-fetoprotein-derived peptides
AASLD LiverLearning®, Eishiro Mizukoshi, 144130
CXCR3-high/CD81-low B cells in Early Acute HCV Infection Correlates with Severity of Liver Inflammation
AASLD LiverLearning®, Mengfei Liu, 144386
Ultra-deep sequencing of circulating tumor DNA identifies druggable mutations: exploring applications of a liquid biopsy in HCC
AASLD LiverLearning®, Ismail Labgaa, 144143
Multidisciplinary Tumor Board Adherence to AASLD Treatment Guidelines for Hepatocellular Carcinoma: Does It Matter?
AASLD LiverLearning®, Asrar AlAhmadi, 144144
Necroptosis and its role in steatohepatitis
AASLD LiverLearning®, Jérémie Gautheron, 144400
Immunological characteristics of the tumor-associated antigens in patients with cholangiocarcinoma
AASLD LiverLearning®, Akihiko Kida, 144145
The FXR/TGR5 Dual Agonist INT-767 Reduces NAFLD Activity Score and Fibrosis Stage and Improves Plasma and Hepatic Lipid Profiles in the GUBRA-AMLN Mouse Model of Diet-induced and Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Jonathan Roth, 144401
Live cell imaging of hepatocyte cytosolic NADH/NAD+ ratio in mouse liver slices
AASLD LiverLearning®, Ricard Masia, 144402
Association of relative liver enhancement of Gd-EOB-DTPA-enhanced magnetic resonance images with histologic grade of hepatocellular carcinoma
AASLD LiverLearning®, Young-Joo Jin, 144159
Quantifying the likely benefits and harms of surveillance for hepatocellular carcinoma in patients with cirrhosis
AASLD LiverLearning®, Ian A. Rowe, 144160
Palmitic acid elicits insulin resistance and oxidative cell injury through clusterization of lipid rafts in murine hepatocytes.
AASLD LiverLearning®, Akira Uchiyama, 144416
Decreased liver volume is an independent predictor of hepatocellular carcinoma in chronic hepatitis B patients on entecavir therapy
AASLD LiverLearning®, Chung Seop Lee, 144161
Sirt6 deletion in liver promotes NASH development by downregulation of Nrf2 in mice fed a high-fat, high-fructose diet.
AASLD LiverLearning®, Sun-O Ka, 144417
Non-alcoholic fatty liver disease derails antiviral immunity in murine viral hepatitis
AASLD LiverLearning®, Ting Wu, 144418
Complete tumor necrosis after loco-regional therapy reduces risk of recurrent HCC after transplant: a UNOS study.
AASLD LiverLearning®, Rex Cheng, 144175
BAP1 modulates expression of long non-coding RNA NEAT1 and contributes to cancer phenotype and sensitivity to gemcitabine in intrahepatic cholangiocarcinoma (iCCA)
AASLD LiverLearning®, Mansi Parasramka, 144176
Trim8 deficiency protects against hepatic steatosis and insulin resistance
AASLD LiverLearning®, peng zhang, 144432
The GALAD serological model may permit earlier diagnosis of hepatocellular carcinoma in a screened cirrhotic population: a re-analysis of a prospective trial
AASLD LiverLearning®, Hiroyuki Yamada, 144177
EDP-305, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits high Potency and Efficacy In Vitro and In Vivo
AASLD LiverLearning®, Lijuan Jiang, 144433
Pirfenidone LP activates PPARα and LXRα and results in decreased expression of proinflammatory cytokines and improvement of NASH features induced by high fat/carbohydrate diet
AASLD LiverLearning®, José Macías-Barragán, 144434
Basic Research Workshop: Program Chair
AASLD LiverLearning®, Mario Strazzabosco, 154677
Aims of the Workshop
AASLD LiverLearning®, Jorge Bezerra, 154680
Dietary Cholesterol Intake Is Not Associated with Hepatocellular Carcinoma Development or Chronic Liver Disease Related Death in the General Population: The United States Multiethnic Cohort
AASLD LiverLearning®, Lei Yu, 144191
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
AASLD LiverLearning®, Masahito Nakano, 144192
Calcium sensing receptor activation increases triglyceride accumulation in HepG2 cells
AASLD LiverLearning®, Pia Villarroel, 144448
Patients with Nonalcoholic Steatohepatitis Cirrhosis Are Significantly Less Likely To Receive Appropriate Screening for Hepatocellular Carcinoma Compared to Patients with Chronic Hepatitis C Virus Cirrhosis
AASLD LiverLearning®, Hesam Tavakoli, 144193
The Mixed Lineage Kinase Inhibitor 3 URMC-009 Attenuates Established Murine Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Brittany Freeman, 144449
Rapid development of NASH in FLS-ob/ob mice and its application for anti-fibrosis evaluation, -Effects of pioglitazone on liver fibrosis and metabolic parameters-
AASLD LiverLearning®, Tadateru Hamada, 144450
Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4)
AASLD LiverLearning®, Tarek Hassanein, 154956
Eight weeks treatment duration with Ledipasvir/Sofosbuvir (LDV/SOF) is effective for appropriately selected patients with genotype 1 Hepatitis C virus (HCV) infection: an analysis of multiple real world cohorts totaling >6,500 patients
AASLD LiverLearning®, Vinay Sundaram, 154957
Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A Review of Spontaneous Post-Marketing Cases
AASLD LiverLearning®, Susan Bersoff-Matcha, 154958
Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation?
AASLD LiverLearning®, Eun Ju Cho, 144207
Hepatobiliary Neoplasia SIG: NASH and HCC: Program Chair
AASLD LiverLearning®, Lopa Mishra, 154703
Retreatment with sofosbuvir + grazoprevir + elbasvir + ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir + ledipasvir or + daclatasvir or + simeprevir regimen (ANRS HC34 REVENGE study)
AASLD LiverLearning®, Victor de Ledinghen, 154959
Insulin resistance assessment is useful in risk stratification of hepatocellular carcinoma in chronic hepatitis B patients
AASLD LiverLearning®, jung hee kim, 144208
Adiponutrin (rs738409) gene polymorphisms increase the risk and progression of nonalcoholic steatohepatitis (NASH) in Asian Indians
AASLD LiverLearning®, Manvi Vernekar, 144464
The Substantial Relationship between Hepatitis B (HBV) and Hepatocecullar carcinoma (HCC): A cross-sectional analysis of HBV and HCC rates from the World Health Organization (WHO) database
AASLD LiverLearning®, Eduardo Rodriguez, 144209
Butyrate induces ROS-mediated apoptosis via modulation of miR-22/SIRT-1 pathway in Hepatoma cells.
AASLD LiverLearning®, Kishor Pant, 144465
Overview: The Relationship Between NASH and HCC
AASLD LiverLearning®, Hashem El-Serag, 154705
Apg2 is a key determinant of hepatic steatosis by regulating AMPK activity
AASLD LiverLearning®, Hiroshi Ishiba, 144466
Efficacy of DRX-065, the stabilized R-enantiomer of pioglitazone (pio), in choline-deficient (CD) and methionine/choline deficient (MCD) diet mouse models of nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Sheila DeWitt, 154972
Endoscopic duodenal mucosal resurfacing (DMR) improves insulin sensitivity, hepatic transaminase levels and anti-inflammatory markers in type 2 diabetes subjects
AASLD LiverLearning®, Harith Rajagopalan, 154973
A single endoscopic duodenal mucosal resurfacing procedure exerts a sustained improvement in hepatic transaminase levels in a cohort of type 2 diabetes patients
AASLD LiverLearning®, Annieke van Baar, 154974
Prognostic significance of sarcopenia in patients with newly diagnosed hepatocellular carcinoma
AASLD LiverLearning®, Yeonjung Ha, 144223
Discovery of new non-invasive tests algorithms (NITs-Algo) for liver disease in subjects with metabolic factors, using SAF scoring system. A proof of concept demonstrating the impact of disease definitions.
AASLD LiverLearning®, Thierry Poynard, 154975
Short term effect of transarterial chemoembolization (TACE) on microsomal liver function by means of 13C-methacetin breath test (MBT) in patients with hepatocellular carcinoma (HCC)
AASLD LiverLearning®, Oliver Goetze, 144224
Combination of an ASK1 inhibitor and FXR agonist increases anti-fibrotic efficacy in a rat model of NASH
AASLD LiverLearning®, Grant Budas, 144480
ALBI grade versus Child-Pugh grade as a grading system for liver function in patients with hepatocellular carcinoma
AASLD LiverLearning®, Seong Kyun Na, 144225
Wheat Bran Autolytic Peptide, Containing a Branched-chain Amino Acid, Improves Nonalcoholic Steatohepatitis with Up-regulation of AMPK/ACC/GSK3β Signaling Pathway in High-fat Diet-fed Mice.
AASLD LiverLearning®, Takumi Kawaguchi, 144481
Rosuvastatin prevents the development of hepatocellular carcinoma in mice with nonalcoholic fatty liver disease.
AASLD LiverLearning®, Keisuke Yokohama, 144482
DPP4 Inhibitor Suppressed Warburg-Dickens Pathway and HCC Progression in a Mouse Model of NASH: A Metabolomic Analysis
AASLD LiverLearning®, Takumi Kawaguchi, 144483
Does Biopsy Aid in the Management of Patients with Hepatocellular Carcinoma Meeting AASLD Diagnostic Imaging Guidelines?
AASLD LiverLearning®, Asrar AlAhmadi, 144239
Incomplete RFA causes cell cycle Arrest and enhanced tumor growth - in vitro and in vivo
AASLD LiverLearning®, Th. Till WISSNIOWSKI, 144240
Dietary Iron overload in the context of a ‘nashogenic’ Western diet aggravates nonalcoholic steatohepatitis through increased recruitment and accumulation of hepatic immune mediators.
AASLD LiverLearning®, Priya Handa, 144496
Hepatocellular Carcinoma Screening in High-Risk Populations in the United States
AASLD LiverLearning®, Manal Hassan, 144241
Regulation of Kupffer cell activation by the microRNA-34a/p53 axis during alcoholic liver injury
AASLD LiverLearning®, Tianhao Zhou, 144497
Exosome Derived from Palmitic Acid-treated Hepatocytes Activates Hepatic Stellate Cells
AASLD LiverLearning®, Young-Sun LEE, 144498
ER Stress Regulates Autophagy and Protein Secretion through IBTKα during the Pathogenesis of Non-Alcoholic Steatohepatitis
AASLD LiverLearning®, Jeffrey Willy, 144499
Yttrium-90 (90Y) Radioembolization in the treatment of intrahepatic cholangiocarcinoma (ICC): Preprocedural biomarkers of response
AASLD LiverLearning®, Xiao Jing Wang, 144255
Time to Initial Treatment of Hepatocellular Carcinoma in an Urban Hospital
AASLD LiverLearning®, Tae Hoon Lee, 144256
Low long term tumor recurrence and mortality rates in patients transplanted for hepatocellular carcinoma listed with low native MELD scores
AASLD LiverLearning®, Heather O'Dell, 144257
A Short-term High Carbohydrate Diet Induces Acute Liver Injury, Enhanced de novo Lipogenesis, Inflammation, Fibrosis and M2 Macrophage Polarization
AASLD LiverLearning®, Yong Ook Kim, 144513
KBP-089, a novel Dual Amylin and Calcitonin Receptor Agonist (DACRA), reduces steatosis of the liver in a rat model of NAFLD/NASH
AASLD LiverLearning®, Sofie Gydesen, 144514
Novel LXR inverse agonists demonstrate anti-steatotic effects in human hepatocytes and in a rat model of NAFLD
AASLD LiverLearning®, Claus Kremoser, 144515
In Hepatocytes, DNA Methylation and Hydroxymethylation Are Altered in Response to Oleic Acid Exposure: A Potential Mechanism for Non-alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Zobair Younossi, 144516
Decellularized Liver Scaffold Promote Liver Regeneration After Partial Hepatectomy
AASLD LiverLearning®, Hirofumi Shimoda, 144271
Extemporanous HR-MAS-NMR metabolomic profiling of back-table liver grafts predicts early graft dysfunction
AASLD LiverLearning®, Francois Faitot, 144272
Projections of non-alcoholic steatohepatitis related liver transplantation waitlist additions
AASLD LiverLearning®, Neehar Parikh, 144273
Interleukin-22 exacerbates liver fibrosis in recurrent hepatitis C after liver transplantation by activating hepatic stellate cells
AASLD LiverLearning®, Hanwei LI, 144529
6 Minute Walk Test: A Quick Standardized Assessment of Functional Status and Pre-Liver Transplant Mortality
AASLD LiverLearning®, Kimberly Forde, 144287
Outcomes for patients listed for liver transplantation with a low Model for End-Stage Liver Disease (MELD) score
AASLD LiverLearning®, Arjmand Mufti, 144288
Sarcopenia in children awaiting liver transplantation.
AASLD LiverLearning®, Eberhard Lurz, 144289
Effect of long term aggressive nutritional therapy on survival in patients with alcoholic liver cirrhosis- Interim analysis of a randomized controlled trial
AASLD LiverLearning®, Chetan Kalal, 144303
Glucose homeostasis in cirrhosis: accuracy of hemoglobin a1c and potential usefulness of continuous glucose monitoring
AASLD LiverLearning®, Andres Duarte-Rojo, 144304
Chronic Opioid Therapy Independently Predicts Readmissions Regardless of HE in a Prospective Cohort of Cirrhotic Patients
AASLD LiverLearning®, Chathur Acharya, 144305
The VITRO Score (Von Willebrand Factor Antigen/ Thrombocyte Ratio) and its diagnostic role as a non-invasive predictor of decompensation and mortality in patients with compensated liver cirrhosis
AASLD LiverLearning®, Remy Schwarzer, 144319
Pulse Oximetry is a Poor Screening Test for Hepatopulmonary Syndrome in Liver Transplant Candidates
AASLD LiverLearning®, Kimberly Forde, 144320
Hyperosmolality is Independently Associated with Severity of Hepatic Encephalopathy in Patients Admitted to Intensive Care Units with Acutely Decompensated Liver Function
AASLD LiverLearning®, Eric Liotta, 144321
Post-Traumatic Stress Disorder can Differentially Affect Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans
AASLD LiverLearning®, Jasmohan S. Bajaj, 144335
Is a simple screening strategy for minimal HE using Stroop Encephalapp enough to predict overt hepatic encephalopathy occurrence?
AASLD LiverLearning®, Andres Duarte-Rojo, 144336
Patients with cirrhosis have highly increased coronary arteriosclerosis
AASLD LiverLearning®, Karen Danielsen, 144337
Alcoholic hepatitis patients have a defect in FOXO3-dependent myeloid cell apoptosis due to high SIRT expression
AASLD LiverLearning®, Zhuan Li, 144095
Effective Prevention of Direct-acting Antiviral-resistant Hepatitis C Virus by Combination with Anti-miR-122 Therapy in Cell Culture
AASLD LiverLearning®, Tetsuro Shimakami, 144351
Myeloid Cell-Specific SIRT1 deficiency Drives Ethanol-Induced Neutrophilic Inflammation and Exacerbates Alcoholic Steatohepatitis in Mice
AASLD LiverLearning®, Min You, 144096
Hepatitis due to HBV reactivation in chronic hepatitis B and C co-infected Chinese treated with direct-acting antivirals
AASLD LiverLearning®, Weicheng Wang, 144352
Corticosteroids are the only remaining pharmacological option for severe alcoholic hepatitis: a meta-analysis of individual data on 1974 patients.
AASLD LiverLearning®, Philippe MATHURIN, 144097
Transcriptome wide characterization of polarized macrophages in the setting of HCV/HIV co-exposure
AASLD LiverLearning®, Shadi Salloum, 144353
Assessment of nutritional status through bioelectrical impedance is a key determinant of outcome in alcoholic hepatitis: a prospective study
AASLD LiverLearning®, Laurent Spahr, 144098
Adipose-specific lipin1 overexpression protects mice against alcohol-induced liver injury
AASLD LiverLearning®, Wenliang Zhang, 144111
HCV-NS2 protease induces growth arrest in Huh7 cells, accompanied by aberrant nuclear localization of E-cadherin and increased WNT1 expression suggestive of epithelial to mesenchymal transition state
AASLD LiverLearning®, Manish Choudhary, 144367
Alcohol-induced activation of the unfolded protein response in Paneth cells induces small intestinal inflammasome activation, pro-apoptotic signaling and IL-17 production
AASLD LiverLearning®, Benedek Gyongyosi, 144112
HCV Cure: Increases Body Weight and Liver Fat Content
AASLD LiverLearning®, Isaac Wasserman, 144368
Hepatic SIRT1 is Dispensable for Adiponectin-Mediated Amelioration of Bile Acid Metabolism Abnormalities and Liver Dysfunction in Ethanol-Fed Mice
AASLD LiverLearning®, Min You, 144113
The Sofosbuvir (SOF) and Velpatasvir (VEL) Regimen is Associated with High Efficacy and Improvement of Patient-Reported Outcomes (PROs) in Patients Co-infected with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV): The Data from ASTRAL-5
AASLD LiverLearning®, Zobair Younossi, 144369
The chemical chaperone 4-phenylbutyric acid prevents ethanol-induced liver injury in diabetic KK-Ay mice
AASLD LiverLearning®, Maiko Suzuki, 144114
Alterations of the gut microbiome in the acute-on-chronic model of alcoholic hepatitis correlate with liver damage, steatosis and inflammation
AASLD LiverLearning®, Patrick Lowe, 144127